Biocon Biologics has entered into a long-term commercial collaboration deal with pharma company Eris Lifesciences that features the sale of Biocon’s metabolics, oncology, and critical care products in the Indian market, for a total transaction value of INR12.4bn ($149m).
Over 430 Biocon employees will be moved to Eris as part of the portfolio transfer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?